<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(1)</volume><submitter>Hjerpe E</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>A deregulated energy metabolism is a hallmark of malignant disease that offers possible future targets for treatment. We investigated the prognostic value of the glycolytic enzymes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate kinase type M2 (PKM2), mitochondrial β-F1-ATPase (ATP5B) and the bioenergetic cellular (BEC) index in advanced ovarian cancer.&lt;h4>Methods&lt;/h4>Fresh tumor samples were prospectively collected from 123 patients undergoing primary surgery for suspected advanced ovarian cancer. Of these, 57 met the eligibility criteria; stage IIC-IV, serous or endometrioid subtype, specimens containing ≥ 50% tumor cells and patients receiving platinum-based chemotherapy. An adequate amount of mRNA could be extracted in all but one case, with a resultant</pubmed_abstract><journal>BMC clinical pathology</journal><pagination>30</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3874631</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer.</pubmed_title><pmcid>PMC3874631</pmcid><pubmed_authors>Carlson J</pubmed_authors><pubmed_authors>Johansson H</pubmed_authors><pubmed_authors>Egyhazi Brage S</pubmed_authors><pubmed_authors>Hjerpe E</pubmed_authors><pubmed_authors>Avall-Lundqvist E</pubmed_authors><pubmed_authors>Frostvik Stolt M</pubmed_authors><pubmed_authors>Shoshan M</pubmed_authors><pubmed_authors>Schedvins K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer.</name><description>&lt;h4>Background&lt;/h4>A deregulated energy metabolism is a hallmark of malignant disease that offers possible future targets for treatment. We investigated the prognostic value of the glycolytic enzymes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate kinase type M2 (PKM2), mitochondrial β-F1-ATPase (ATP5B) and the bioenergetic cellular (BEC) index in advanced ovarian cancer.&lt;h4>Methods&lt;/h4>Fresh tumor samples were prospectively collected from 123 patients undergoing primary surgery for suspected advanced ovarian cancer. Of these, 57 met the eligibility criteria; stage IIC-IV, serous or endometrioid subtype, specimens containing ≥ 50% tumor cells and patients receiving platinum-based chemotherapy. An adequate amount of mRNA could be extracted in all but one case, with a resultant</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013 Nov</publication><modification>2025-04-04T22:17:35.535Z</modification><creation>2019-03-27T01:19:07Z</creation></dates><accession>S-EPMC3874631</accession><cross_references><pubmed>24252137</pubmed><doi>10.1186/1472-6890-13-30</doi></cross_references></HashMap>